CareDx director Richard Riggsbee sells $395,137 in shares
Richard Bryan Riggsbee, a director at CareDx, Inc. (NASDAQ:CDNA), sold 5,285 shares of common stock totaling $395,137 on November 16, 2026, through a Rule 10b5-1 trading plan. The sales occurred at weighted average prices between $74.0181 and $77.0225 per share. Following these transactions, Mr. Riggsbee directly owns 34,027 shares, while InvestingPro analysis suggests the stock is currently overvalued despite a 366% gain over the past year.
Form 4 Caredx Inc: Richard Bryan Riggsbee (Director) For: 16 November
This article reports on a Form 4 filing for CareDx Inc., detailing a transaction involving Director Richard Bryan Riggsbee on November 16. It includes the stock symbol CDNA and notes a slight decrease in its value. The content primarily focuses on this insider trading announcement.
In four trades on Nov. 16, a CareDx (CDNA) director sold 5,285 shares under a preset trading plan.
CareDx, Inc. (CDNA) director Richard Bryan Riggsbee sold a total of 5,285 shares of common stock on November 16, 2026, across four separate transactions. These sales were executed under a Rule 10b5-1 trading plan that was adopted on August 4, 2026, with weighted-average prices ranging from $74.0181 to $77.0225 per share. Following these transactions, Riggsbee's direct holdings in CareDx common stock decreased from 39,312 to 34,027 shares.
CareDx (CDNA) CFO sells shares under a trading plan adopted August 6, 2026.
CareDx, Inc. (CDNA) CFO & COO Keith Kennedy exercised options to acquire 2,097 common shares on November 12, 2026, at an exercise price of $29.43 per share. On the same day, he sold 800 shares at a weighted-average price of $78.7825 per share and 1,297 shares at a weighted-average price of $79.6068 per share, both transactions conducted under a Rule 10b5-1 trading plan adopted on August 6, 2026. Following these transactions, Kennedy's option position was 46,132 shares, and his common stock holdings were 199,147 shares.
Wall Street Analysts Think CareDx (CDNA) Could Surge 28.09%: Read This Before Placing a Bet
Wall Street analysts project CareDx (CDNA) could see a 28.09% upside, with a mean price target of $94.43. Despite the skepticism around price targets, strong agreement among analysts on higher earnings estimates, coupled with a Zacks Rank #1 (Strong Buy), suggests potential for near-term stock appreciation. Investors are advised to use price targets as a starting point for further research rather than the sole basis for investment decisions.
10,570 shares are slated for sale by a CareDx (CDNA) director’s trust.
CareDx, Inc. director Richard Bryan Riggsbee's Revocable Trust plans to sell 10,570 common shares of CDNA, with an aggregate market value of $823,192. These shares were acquired through RSU vesting on June 14, 2025. The approximate sale date is November 16, 2026, or within three months of the notice, with a Rule 10b5-1 plan adoption date of August 4, 2026.
CareDX Inc Lobbying Profile, 2018
This OpenSecrets profile details CareDX Inc.'s federal lobbying activities, expenditures, and the firms and lobbyists it employed. As of July 23, 2026, CareDX Inc. had spent $260,000 on direct lobbying efforts in 2026, operating within the Pharmaceuticals/Health Products industry. The profile provides a summary of their lobbying activities, including hired firms, lobbyists, issues addressed, agencies targeted, and relevant bills.
After exercising 15,000 options, CareDx (CDNA) director George Bickerstaff holds 149,061 shares directly.
CareDx, Inc. director George Bickerstaff exercised 15,000 fully vested stock options on November 10, 2026, at an exercise price of $14.74 per share. Following this transaction, his reported option position became zero, and he directly held 149,061 shares of common stock. This insider trading activity was reported in an SEC Form 4 filing on November 12, 2026.
State Street reports more than 2.6 million CareDx (CDNA) shares in a passive stake.
State Street Corporation has reported a 5.1% passive stake in CareDx, Inc. (CDNA), holding 2,623,064 common shares as of September 30, 2026. The financial institution holds shared voting power over 2,505,109 shares and shared dispositive power over 2,623,064 shares. This disclosure, filed as a SCHEDULE 13G, indicates that the shares were acquired in the ordinary course of business and not for the purpose of influencing company control.
Form 4 Caredx Inc: Keith Kennedy (CFO & COO) For: 5 November By Investing.com
This article reports on a Form 4 filing for Caredx Inc, indicating a transaction by Keith Kennedy, the company's CFO and COO, on November 5th. The brief notice from Investing.com is part of their coverage of stock market news, specifically insider trading activities.
Caredx CFO & COO Keith Kennedy sells $4.8M in company stock
Keith Kennedy, CFO and COO of CareDx, Inc. (NASDAQ:CDNA), sold 61,961 shares of company stock for approximately $4.8 million on November 5, 2026. These sales were part of a Rule 10b5-1 trading plan, following his acquisition of shares through employee stock options. CareDx recently reported strong third-quarter results, exceeding expectations and leading analysts to raise price targets, although InvestingPro analysis suggests the stock is currently overvalued.
A trading plan covers CareDx (CDNA) CFO's 61,961-share sale; he also exercises 52,422 options.
CareDx, Inc.'s CFO & COO, Keith Kennedy, exercised options for 52,422 common shares at $29.43 on November 5, 2026. On the same day, he sold 61,961 common shares across eight transactions under a Rule 10b5-1 trading plan, with reported per-share amounts ranging from $76.5485 to $83.6000. Following these transactions, his reported option position was 48,229 shares, and his direct common stock holdings were 199,147 shares.
After 1,505 shares are withheld for taxes, CareDx (CDNA) counsel Novack holds 100,700 shares directly.
Jeffrey Adam Novack, Secretary and General Counsel of CareDx, Inc. (CDNA), had 1,505 shares withheld by the issuer on November 6, 2026, to cover tax obligations related to the vesting of restricted stock units. Following this transaction, Novack directly holds 100,700 shares of common stock. This information was reported in a Form 4 SEC filing.
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 6, 2026
CareDx, Inc. (Nasdaq: CDNA) announced inducement grants awarded to 21 new employees on November 5, 2026. These grants consist of restricted stock units (RSUs) totaling 33,375 shares of common stock, which will vest over four years. The awards were made under the company's 2025 Inducement Equity Incentive Plan, adhering to Nasdaq Listing Rule 5635(c)(4).
Cathie Wood’s ARK sells CareDx stock, buys Natera and Kratos
Cathie Wood's ARK ETFs executed several trades on November 6, 2026, selling 113,168 shares of CareDx, Inc. (CDNA) for over $8.6 million. Simultaneously, ARK made significant purchases, acquiring 61,961 shares of Natera, Inc. (NTRA) for approximately $22.5 million and 139,142 shares of Kratos Defense & Security Solutions, Inc. (KTOS) for about $4.6 million, signaling strategic shifts in its portfolio. The firm also continued to accumulate Alphabet Inc. (GOOG) and Coinbase Global, Inc. (COIN) stock.
58,713 option shares are part of a CareDx (CDNA) officer's proposed stock sale.
CareDx (CDNA) officer Keith S. Kennedy has filed notice for a proposed sale of 79,243 common shares, valued at an aggregate market value of $6,803,803.98. This sale includes 58,713 shares expected from stock-option exercises over the next three months, along with shares from an Employee Stock Purchase Plan, restricted stock units, and performance stock units. Morgan Stanley Smith Barney LLC is listed as the broker for the transaction.
Form 4 Caredx Inc: Jeffrey Adam Novack (Secretary and General Counsel) For: 1 November By Investing.com
This article reports on a Form 4 filing for CareDx Inc. indicating an insider transaction by Jeffrey Adam Novack, who serves as the Secretary and General Counsel of the company. The transaction date specified is November 1st. The filing pertains to stock market activities and is published by Investing.com.
Counsel retains 102,205 shares after CareDx (CDNA) withholds 2,873 shares for taxes.
CareDx, Inc. (CDNA) withheld 2,873 shares from Secretary and General Counsel Jeffrey Adam Novack on November 1, 2026, to cover tax obligations related to the vesting of restricted stock units. The shares were valued at $85.88 each. Following this transaction, Novack directly holds 102,205 shares.
Form 4 Caredx Inc: Jeffrey Adam Novack (Secretary and General Counsel) For: 1 November
This article reports on a Form 4 filing for CareDx Inc. It details that Jeffrey Adam Novack, Secretary and General Counsel of CareDx Inc., made a filing for November 1st. The article provides basic information about the insider transaction, highlighting the company and the individual involved.
CareDx Q3 Earnings Call Highlights Raised '26 Outlook & Testing Growth
CareDx (CDNA) has raised its 2026 revenue and profitability outlook, citing strong demand for transplant testing, improved reimbursement, and contributions from its new specialty oncology business, Naveris. During its Q3 2026 earnings call, the company highlighted expanding clinical adoption, enhanced testing economics, and plans to commercialize new molecular diagnostics in 2027. CareDx also discussed future reimbursement opportunities and its longer-term growth expectations with analysts.
CareDx Q3 Earnings Call Highlights Raised '26 Outlook & Testing Growth
CareDx (CDNA) raised its 2026 revenue and profitability outlook after a strong third quarter driven by transplant testing demand and contributions from its specialty oncology business, Naveris. The company saw increased transplant testing volumes and expanded commercial capabilities for NavDx, with management focusing on clinical adoption, improved testing economics, and the preparation of new molecular diagnostics for launch in 2027. CareDx aims for higher reimbursement per test and maintains expense discipline while expecting continued growth in both transplant and specialty oncology segments.
CareDx kidney test trajectories linked to 3-year transplant outcomes
CareDx announced the publication of a study in Transplantation which found a link between early post-transplant AlloSure Kidney donor-derived cell-free DNA (dd-cfDNA) levels and three-year kidney allograft outcomes. Patients with persistent dd-cfDNA elevation in the first four months had a nine-fold higher incidence of allograft loss compared to those with consistently low levels, while transient elevations that resolved were not associated with worse outcomes. The findings indicate that the pattern of dd-cfDNA changes can predict long-term graft outcomes, with 83.7% of recipients having consistently low levels and favorable outcomes.
H.C. Wainwright Maintains CareDx(CDNA.US) With Hold Rating, Raises Target Price to $90
H.C. Wainwright has reiterated its Hold rating on CareDx (CDNA.US) while simultaneously increasing its price target for the company's shares to $90. This adjustment reflects the analyst firm's updated outlook on CareDx's valuation and market position.
Weekly Recap: Raised guidance and transplant testing growth
CareDx, Inc. (CDNA) reported strong Q3 2026 results, beating revenue estimates with a 39% increase and 21% growth in transplant tests, leading to raised 2026 guidance. The company also acquired Naveris, sold its lab-products business for a significant gain, and is on track for 2027 product launches. BTIG raised its price target for CDNA, while ARK Genomic Revolution ETF (ARKG) sold some shares.
CareDx, Inc. Just Beat EPS By 775%: Here's What Analysts Think Will Happen Next
CareDx, Inc. (NASDAQ:CDNA) significantly surpassed analyst expectations in its third-quarter results, with revenues 14% higher than forecast and EPS beating models by 775%. Following these strong results, analysts have updated their models, upgrading revenue forecasts for 2027 and making a decent improvement in earnings per share, leading to a 34% increase in the price target to US$86.17 per share. Despite expecting an acceleration in growth, CareDx is projected to grow slower than the industry average.
CareDx, Inc. Stock 12‑Month Price Target Raised to $86.17, Implies 20% Upside
The average 12-month price target for CareDx, Inc. (CDNA) stock has been raised from $65.33 to $86.17 by 6 analysts, implying a 20% potential upside from its Oct. 29 closing price. The consensus rating among 7 analysts remains a "Buy," with 5 Buys and 2 Holds. Investors can find more detailed price target data and analyst recommendations on TradingView's platform.
CareDx, Inc. Stock 12‑Month Price Target Raised to $86.17, Implies 20% Upside
CareDx, Inc.'s average stock price target has been increased from $65.33 to $86.17, with estimates ranging from $46 to $100 per share. This new target suggests a potential upside of approximately 20% based on the October 29 closing price. The consensus rating from 7 analysts remains at "Buy," comprising 5 Buys and 2 Holds.
CareDx Raises 2026 Outlook as Q3 Revenue Grows 39%
CareDx Inc. has increased its full-year 2026 revenue and adjusted EBITDA guidance after reporting a 39% rise in third-quarter revenue, driven by strong transplant testing growth and the integration of its specialty oncology business. The company now anticipates 2026 revenue between $520 million and $530 million and adjusted EBITDA from $90 million to $100 million. CareDx reported third-quarter revenue of $139.4 million and adjusted EBITDA of $30.5 million, ending the quarter with $250 million in cash and no debt.
CareDx Announces Third Quarter 2026 Financial Results
CareDx (Nasdaq: CDNA) reported strong third-quarter 2026 financial results, with revenue increasing 39% year-over-year to $139 million, driven by growth in Testing Services and Patient and Digital Solutions. The company raised its full-year 2026 revenue guidance to a range of $520 million to $530 million and adjusted EBITDA guidance to $90 million to $100 million. Key highlights include the acquisition of Naveris, Inc. and advancements in pipeline programs like AlloHeme and HistoMap Kidney.
Caredx Inc stock hits 52-week high at 72.74 USD
Caredx Inc stock achieved a 52-week high of 72.74 USD, driven by a 405.46% increase over the past year and strong Q2 2026 results that surpassed analyst expectations. While InvestingPro analysis suggests the stock is overvalued, it boasts a perfect Piotroski Score of 9 and an attractive PEG ratio of 0.29. Analysts have responded with mixed ratings, with some raising price targets and others reiterating neutral stances.
BTIG raises CareDx stock price target to $81 on revenue outlook By Investing.com
BTIG has increased its price target for CareDx (NASDAQ: CDNA) shares to $81 from $74, maintaining a Buy rating due to anticipated upside in 2027 revenue estimates and recent strong stock performance. The firm expects CareDx to beat revenue projections, building on its recent second-quarter 2026 results that surpassed analyst forecasts. CareDx specializes in diagnostic surveillance solutions for transplant patients.
BTIG raises CareDx stock price target to $81 on revenue outlook
BTIG has increased its price target for CareDx (NASDAQ:CDNA) shares to $81 from $74, maintaining a Buy rating, due to the stock's recent strong performance, including a 376% return over the past year. The firm expects CareDx to surpass 2027 revenue estimates and projects a 5% revenue beat in upcoming results. This follows CareDx's stronger-than-expected Q2 2026 results and raised full-year outlook.
Responsive Playbooks and the CDNA Inflection
This article provides an in-depth AI-driven analysis of Caredx Inc. (NASDAQ: CDNA), highlighting strong sentiment across all horizons and compelling upside potential due to the absence of resistance levels above the current price. It details three distinct institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to guide investors. The report emphasizes the predictive AI's ability to generate real-time entry and exit signals, risk-reward ratios, and personalized alerts for optimizing trading decisions.
CareDx to Report Q3 Earnings: Transplant Testing Growth in Focus
CareDx (CDNA) is set to release its third-quarter 2026 results, with analysts expecting revenues of $122.4 million, up 22.3% year-over-year, and EPS of 24 cents, a 14.3% decline. The company's performance is anticipated to be driven by strong demand in transplant testing services, strategic divestitures, and recent acquisitions, despite potential pressure from declining out-of-period revenues and investments in its specialty oncology business. The article also highlights other medical stocks with strong potential for earnings beats.
CareDx to Report Q3 Earnings: Transplant Testing Growth in Focus
CareDx (CDNA) is expected to release its third-quarter 2026 earnings soon, with analysts forecasting increased revenues driven by growth in Testing Services and Patient and Digital Solutions. The company's strategic divestiture of its Lab Products business and acquisition of Naveris, coupled with strengthened Medicare coverage for AlloSure and AlloMap, are anticipated to contribute to top-line growth. While investments in specialty oncology may impact EBITDA margins, CareDx's strong financial position and operational capabilities are expected to support continued business expansion.
Enterprise value to revenue forward of CareDx, Inc. – NASDAQ:CDNA
This article focuses on the enterprise value to revenue forward of CareDx, Inc. (NASDAQ: CDNA). It appears to be a financial data point presented on the TradingView platform, which provides market information and tools for investors. The content itself is very minimal, mainly comprising the headline and extensive navigation/footer text from the TradingView website.
CareDx awards 15,822 RSUs to Executive Advisor James McNally
CareDx, Inc. (NASDAQ: CDNA) awarded 15,822 restricted stock units (RSUs) to James McNally upon his appointment as Executive Advisor on July 30, 2026. These equity grants serve as an inducement for his service and align his compensation with long-term shareholder value, complying with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest in two equal tranches on January 2, 2027, and July 2, 2027, provided McNally continues his service with the company.
CareDx, Inc. Estimates – HAM:1K9
This article provides financial estimates and actuals for CareDx, Inc. (HAM:1K9) on the Hamburg Stock Exchange, accessible via TradingView. It allows users to explore reported financial data and analyst estimates across various statements and valuation metrics. The platform enables comparison of actual results with average, high, and low estimates, and visualization of trends over time.
CareDx, Inc. Estimates – HAM:1K9
This article from TradingView provides an overview of CareDx, Inc. (HAM:1K9) on the Hamburg Stock Exchange, focusing on its financial estimates. Users can explore reported financial data and analyst estimates across various statements, compare actual results with average, high, and low estimates, and visualize trends over time. The platform also offers tools for income statements, balance sheets, cash flow, and annual/quarterly data.
CareDx Reports AlloSure Kidney Data Showing Nearly Threefold Higher Risk of Adverse Transplant Outcomes
CareDx, Inc. announced new clinical findings at Kidney Week 2026, revealing that elevated levels of its AlloSure Kidney diagnostic test are associated with a nearly threefold higher risk of adverse graft outcomes in kidney transplant recipients. Additional research indicated that blood-based monitoring with donor-derived cell-free DNA significantly reduced the need for routine surveillance biopsies without compromising clinical outcomes. These studies support the use of molecular biomarkers in assessing transplant injury and guiding clinical decisions, though they do not suggest blood-based testing can fully replace biopsies in all scenarios.
CareDx Announces New KOAR Data Linking Elevated AlloSure® Kidney to Nearly 3-Fold Higher Risk of Adverse Graft Outcomes in Patients with Borderline Rejection or TCMR at ASN Kidney Week 2026
CareDx announced new data from its KOAR registry and other studies at ASN Kidney Week 2026, highlighting the efficacy of its AlloSure Kidney and AlloSure Plus tests. The data indicates that elevated AlloSure Kidney levels are associated with a nearly 3-fold higher risk of adverse graft outcomes in kidney transplant patients with borderline rejection or TCMR. Additionally, a randomized trial showed AlloSure-based monitoring significantly reduced the need for invasive biopsies while maintaining similar clinical outcomes, and the tests maintained strong rejection prediction under updated Banff 2024 criteria.
CareDx links AlloSure Kidney to adverse graft outcomes
CareDx (NASDAQ: CDNA) reported findings from a 131-patient registry analysis showing that elevated AlloSure Kidney results were associated with nearly three times the risk of poor transplant outcomes. While this supports risk assessment, it does not confirm that treatment guided by the test prevents graft loss. Separately, a randomized trial highlighted by CareDx indicated that blood-marker monitoring reduced kidney biopsies by 49% compared to invasive biopsy monitoring.
Caredx Inc stock hits 52-week high at 72.61 USD By Investing.com
CareDx Inc. (CDNA) stock recently hit a 52-week high of $72.51, reflecting a 356% increase over the past year and a 267% year-to-date return. The company reported strong Q2 2026 results, surpassing analyst expectations for earnings and revenue, and received positive analyst ratings and raised price targets. InvestingPro data indicates strong fundamentals, despite the stock trading above its Fair Value.
CareDx Faces First NavDx Quarter With Street Estimates Trailing Its Raised Outlook
CareDx is approaching its Q3 earnings report on October 29 with an unusual situation where management has repeatedly raised its full-year revenue outlook, but Street consensus estimates still lag significantly. This quarter is the first to include the newly acquired NavDx oncology business and exclude the divested lab products line, offering a cleaner look at the company's financial performance. Analysts expect non-GAAP earnings of $0.24 a share on $122.4 million in revenue, while the company's own full-year guidance of $490 million to $500 million is well above the consensus of $455 million.
Las ETF que invierten en acciones de CareDx, Inc.
This article lists various Exchange Traded Funds (ETFs) that hold shares of CareDx, Inc. (1K9), providing details such as market value, weight, issuer, management style, expense ratio, and total return. The ETFs listed cover diverse investment strategies including biotech, small-cap, extended market, and genomic revolution, offering investors different avenues with varying risk profiles. The information aims to facilitate investment decisions by presenting key statistics for each fund.
Caredx Inc stock hits 52-week high at 72.61 USD
CareDx Inc. (CDNA) stock recently achieved a 52-week high of $72.51, reflecting a 356% increase over the past year and a 267% year-to-date return. This surge follows stronger-than-expected Q2 2026 results, with the company surpassing analyst forecasts for both adjusted earnings and revenue. Analysts have reacted positively, with some raising price targets and initiating Buy ratings, reinforcing confidence in the company's performance and leadership in transplant diagnostics.
Caredx Inc stock hits 52-week high at 72.61 USD By Investing.com
CareDx Inc (CDNA) stock recently hit a 52-week high of $72.51, reflecting a 356% increase over the past year and a 267% year-to-date return. The company reported stronger-than-expected Q2 2026 results with significant revenue growth, and analysts have largely maintained positive ratings and raised price targets. InvestingPro highlights strong fundamentals, though the stock trades above its Fair Value.
Price to earnings ratio of CareDx, Inc. – HAM:1K9
This article displays the price to earnings ratio for CareDx, Inc. (HAM:1K9) on the Hamburg Stock Exchange. It notes that the market is currently closed with no trades. The data is provided by ICE Data Services and FactSet Research Systems Inc.
Basic earnings per share (basic EPS) of CareDx, Inc. – HAM:1K9
This article focuses on the basic earnings per share (basic EPS) for CareDx, Inc. (HAM:1K9), a company listed on the Hamburg Stock Exchange. The current market status shows no trades, indicating the market is closed. The content primarily serves as a financial data point for investors tracking CareDx.
Long term debt to total assets ratio of CareDx, Inc. – HAM:1K9
This article provides the long-term debt to total assets ratio for CareDx, Inc. (HAM:1K9), indicating no trades and a closed market on the Hamburg Stock Exchange. It highlights the company's financial data, which is provided by ICE Data Services and FactSet.